Nadim Tawil

Nadim Tawil

Auto-generated profile, based on publicly available information

Nadim Tawil

Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
NTNadim Tawil
Nadim Tawil
RBRayhaan Bassawon
Rayhaan Bassawon
BMBrian Meehan
Brian Meehan
ANAli Nehme
Ali Nehme
LMLaura Montermini
Laura Montermini
JRJanusz Rak
Janusz Rak
Vascular anomalies, including local and peripheral thrombosis, are a hallmark of glioblastoma (GBM) and an aftermath of deregulation of the cancer cell genome and epigenome. Although the molecular effectors of these changes are poorly understood, the upregulation of podoplanin (PDPN) by cancer cells has recently been linked to an increased risk for venous thromboembolism (VTE) in GBM patients. Therefore, regulation of this platelet-activating protein by transforming events in cancer cells is of considerable interest. We used single-cell and bulk transcriptome data mining, as well as cellular and xenograft models in mice, to analyze the nature of cells expressing PDPN, as well as their impact on the activation of the coagulation system and platelets. We report that PDPN is expressed by distinct (mesenchymal) GBM cell subpopulations and downregulated by oncogenic mutations of EGFR and IDH1 genes, along with changes in chromatin modifications (enhancer of zeste homolog 2) and DNA methylation. Glioma cells exteriorize their PDPN and/or tissue factor (TF) as cargo of exosome-like extracellular vesicles (EVs) shed from cells in vitro and in vivo. Injection of glioma-derived podoplanin carrying extracelluar vesicles (PDPN-EVs) activates platelets, whereas tissue factor carrying extracellular vesicles (TF-EVs) activate the clotting cascade. Similarly, an increase in platelet activation (platelet factor 4) or coagulation (D-dimer) markers occurs in mice harboring the corresponding glioma xenografts expressing PDPN or TF, respectively. Coexpression of PDPN and TF by GBM cells cooperatively affects tumor microthrombosis. Thus, in GBM, distinct cellular subsets drive multiple facets of cancer-associated thrombosis and may represent targets for phenotype- and cell type–based diagnosis and antithrombotic intervention.

19 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LALata Adnani
Lata Adnani
JKJordan Kassouf
Jordan Kassouf
BMBrian Meehan
Brian Meehan
CSCristiana Spinelli
Cristiana Spinelli
NTNadim Tawil
Nadim Tawil
JRJanusz Rak
Janusz Rak
Glioblastoma (GBM) is an incurable form of primary astrocytic brain tumor driven by glioma stem cell (GSC) compartment closely associated with the vascular niche. GSC phenotypes are heterogeneous and range from proneural to mesenchymal-like, the latter characterised by greater invasiveness. Here we document the secretory (angiocrine) role of endothelial cells and their derived extracellular vesicles (EVs) as drivers of proneural-to-mesenchymal reprogramming of GSCs. These changes involve activation of matrix metalloproteinases (MMPs) and NFκB, and inactivation of NOTCH, while altering responsiveness to chemotherapy and driving infiltrative growth in the brain. Our findings suggest that EV-mediated angiocrine interactions impact the nature of cellular stemness in GBM with implications for disease biology and therapy.

22 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
WJWajih Jawhar
Wajih Jawhar
GDGeoffroy Danieau
Geoffroy Danieau
AAAlva Annett
Alva Annett
TITakeaki Ishii
Takeaki Ishii
ABAndrea Bajic
Andrea Bajic
LGLivia Garzia
Livia Garzia
Osteosarcomas (OS) are aggressive bone tumors known for their extensive structural variations and rare recurrent oncogenic driver mutations. In this study, we identify ectopic expression of the oncohistone-mimic EZHIP in 20% of patients across two independent OS cohorts. We demonstrate that reduced deposition of the repressive H3K27me3 mark correlates with poor histological response to neoadjuvant therapy, serving as a predictor of patient outcomes. Through gain- and loss-of-function experiments, we provide functional evidence of the oncogenic activity of EZHIP in enhancing the aggressive characteristics of OS both in vitro and in vivo. EZHIP-induced epigenetic reprogramming reactivates developmental pathways and impedes the differentiation of mesenchymal progenitors, pushing them towards smooth muscle lineage commitment at the cost of other fates. Targeting residual H3K27me3 with EZH2 inhibitors may offer therapeutic benefit in EZHIP-expressing OS. Our findings highlight EZHIP expression as a prevalent driver in OS, offering insights into its pathogenic mechanisms and potential therapeutic strategies for this debilitating cancer.

16 May 2024 in Bleeding, Thrombosis and Vascular Biology
Verified
Journal Article
Open access
PDF file
NTNadim Tawil
Nadim Tawil
LALata Adnani
Lata Adnani
JRJanusz Rak
Janusz Rak
Cancer-associated thrombosis (CAT) results from the hemostatic system being dysregulated by the progression of cancer. Despite common clinical manifestations, the mechanisms of CAT may vary greatly because cancers develop along distinct biological trajectories that are imposed by the interaction between the tumor cell genome, the epigenome, the surrounding microenvironment, and the tissue of origin. The coagulome, or repertoire of coagulation effectors, expressed by stromal, inflammatory, and cancer cells at the tumor-vascular interface and systemically, reflects this biological variability. Complex landscapes of coagulant and non-coagulant cellular populations are revealed by single-cell RNA sequencing analyses conducted on unperturbed human cancer tissues. Additionally, through mediators of cell-cell interactions, soluble coagulants, and extracellular vesicles containing tissue factor, podoplanin, and other effectors, coagulomes are projected into the pericellular milieu and systemic circulation. As this complexity is currently outside of the clinical paradigm, one could argue that better CAT management could result from a more individualized analysis of coagulomes in cancer patients.